Drugs / OMT-111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04520386 | Oct 2020 → Jun 2022 | breast cancer, lung cancer, pancreatic adenocarcinoma | MetiMedi Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMT-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04520386 ↗ |